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Performance Measurement Methodology: New Insights November 16, 2010:1767–82troduction
nce the publication of the initial American College of
ardiology (ACC)/American Heart Association (AHA)
ethodology for the Selection and Creation of Performance
easures (1), there has been an explosion in the development
d application of performance measures. Although initially
visioned as a means for physician-led quality-improvement
forts, performance measures have been primarily used as
ols for accountability and performance-based reimburse-
ent instead. Given the centrality of and experience with
rformance measures for quantifying healthcare quality, the
merican College of Cardiology Foundation (ACCF)/AHA
ask Force on Performance Measures sought to update its
ethodology so that ongoing efforts to measure performance
uld benefit from emerging insights. The original method-
ogy, proposed in 2005 (1), remains the foundation for
veloping process performance measures. The principal
commendations of the 2005 report are summarized in Table 1.
he 2010 report does not address detailed issues of analysis
), pay for performance (4), or nonfinancial rewards for
tter performance (5) because these topics have been ad-
essed in other statements. The focus of the 2010 report is to
ovide a state-of-the-art perspective on the construction,
llection, and emerging directions of performance measure-
ent as a means to improve healthcare quality.
ble 1. ACCF/AHA Attributes of Performance Measures
Choosing Performance Measures
lection Factors Considerations
herence to the potential
rformance measure
sults in meaningful
provements in clinically
portant outcomes
Evidence-based trials, strong clinical
practice guideline recommendations for
(Class I, Level of Evidence: A) or against
(Class III, Level of Evidence: A) the
measure
oad sampling from
ultiple domains associated
th the process of medical
re (see Figure 1)
Measures should be distributed across the
domains of diagnosis, patient education,
treatment, patient self-management, and
serial monitoring of success of treatment
Attributes of Selected Measures
easure Characteristics Relevant Attributes
eful in improving patient
tcomes
Interpretable
Actionable
easure design Denominator precisely defined
Numerator precisely defined
Established types of validity
● Face
● Content
● Construct
Established reliability
easure implementation Feasibility
● Reasonable effort
● Reasonable cost
● Reasonable time period for collection
erall assessment by
rformance Measures
riting Group
Overall assessment of measure by explicit,
predefined criteria for inclusion in
measurement setdiAdapted from Normand SL et al (2).It is important to contextualize the creation of performance
easures in light of the new and existing metrics for
aluating health care. Clinical practice guidelines, such as
ose developed by the ACCF/AHA Task Force on Practice
uidelines (6), remain the primary activity through which the
pidly evolving clinical literature is evaluated and synthe-
zed. These guidelines provide an evidentiary review and
commendations that support patient care. Through direct
kages to scientific evidence, guidelines are the foundation
derpinning most efforts to improve the quality of care.
ppropriate use criteria identify common, prototypical pa-
nt subgroups for which expert clinicians, using available
idence from the guidelines and medical literature, assess
e benefits and risks of a test or procedure on patient
tcomes. Appropriate use criteria are a framework with
hich to examine the rational use of diagnostic and thera-
utic procedures to support a more efficient use of medical
sources, a major goal of the U.S. healthcare system (7).
ch criteria arose from the observation that use of proce-
res varied across the nation, and it was not clear whether
me patients were undertreated or others overtreated. The
imary goals of appropriate use criteria are to identify
eruse (patients who received unnecessary therapy) to im-
ove the safety and cost-effectiveness of care.
Performance measures that articulate discrete processes of
re, as opposed to structural aspects of care or outcomes, are
stinctly different from both clinical practice guidelines and
propriate use criteria because they represent a subset of the
inical guidelines for which the evidence is sufficiently
rong: typically where the highest-quality evidence of benefit
equivocally exceeds risk (Class I recommendation, Level
Evidence: A) (8), failure to provide the therapy to an
igible patient meaningfully reduces the likelihood that the
tient will experience the best possible outcome. In this
port, the writing committee, commissioned by the Task
rce on Performance Measures, discusses new insights into
e selection of performance measures, including the strength
evidence needed to consider creating a performance
easure from a clinical guideline and the role of costs in
nsidering selection of a performance measure for an ex-
nsive technology. The committee then describes new in-
ghts into the construction of performance measures (cre-
ion of exclusions, use of outcomes measures, numbers of
easures, and modification/retirement of measures). Finally,
e implementation and analysis of performance measures are
gure 1. An overview of the steps in providing care by domain.
eprinted from Spertus et al (1).scussed, including the use of composite measures and
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November 16, 2010:1767–82 Performance Measurement Methodology: New Insightstribution as the foundation for a continually growing and
proving healthcare system.
. New Insights Into the Selection of
ossible Performance Measures
.1. Abbreviations Used Throughout
e Report
MI, acute myocardial infarction
MS, Centers for Medicare and Medicaid Services
2B, American College of Cardiology Foundation Door-to-
Balloon Alliance
MRs, electronic medical records
ER, incremental cost-effectiveness ratio
R, international normalized ratio
M, Institute of Medicine
I, myocardial infarction
CQA, National Committee for Quality Assurance
QF, National Quality Forum
I, percutaneous coronary intervention
PI, American Medical Association–Physician Consortium
for Performance Improvement
.2. Strength of Evidence
itial recommendations for construction of a performance
easurement set (1) involved: 1) evaluating the strength of
idence supporting a potential performance measure, 2)
fining the clinical significance of the outcome most likely
be achieved by adherence to a performance measure, and
assessing the magnitude of the association between adher-
ce to the potential performance measure and a clinically
portant outcome. Because there can be strong financial
centives for a manufacturer to have its diagnostic or
erapeutic products included in a performance measure, a
early articulated approach to the selection of performance
easures is needed. The writing committee reviewed current
rspectives to determine how to select performance mea-
res that could improve patients’ health in clinically mean-
gful ways.
An important concept in the selection of performance
easures is confidence that the selected measures will mean-
gfully improve the health—either survival or health status
atients’ symptoms, function, and quality of life)—of the
pulation to whom the measures are applied. For perfor-
ance measures other than outcomes, writing committees
ould clearly establish that the selected process or structural
rformance measures have a strong association with clini-
lly meaningful outcomes. The strength of this association
n be measured in a number of different ways through a
alitative or a quantitative assessment of the likely benefit
d the range of uncertainty about the size of that benefit.
nder the current paradigm, clinical practice guideline writ-
g committees classify information obtained from mixtures
randomized clinical trials, nonrandomized studies, expert
nel consensus, and case studies to create a hierarchical mading system. This system integrates the methodological
ality of the underlying evidence (level of evidence, from
e highest [A] to the lowest [C]) and the trade-off between
nefit and risk (class of recommendation, from the highest
] to the lowest [III]) (8). In comparing risks and benefits,
riting committees ultimately develop a qualitative sense that
e benefits outweigh the risks. However, this qualitative
sessment is usually based on the number and type of
pportive studies rather than the clinical importance of the
served differences in outcome (6,8). By design this ap-
oach elevates ratings to those studies where statistically
gnificant differences in outcomes are replicated in several
ndomized clinical trials. Reliance on statistically significant
fferences indicates that there was some benefit from the
tervention, however. In an era where many studies use
mbined end points, though, rather than relying solely on
ortality or quality of life, less-important outcomes (includ-
g surrogates) may drive the statistical significance of a trial.
fact, because industry-funded clinical trials are primarily
signed to provide data to support regulatory approval of a
vel treatment and because the U.S. Food and Drug Admin-
tration often requires several supportive trials to grant
proval, industry trials are often large and replicated. In
ntrast, nonindustry-sponsored trials, such as those spon-
red by the National Institutes of Health or the Veterans
ffairs healthcare system, are rarely repeated. Although
plication of scientific findings is a key tenet in assessing
use and effect, the strength, accuracy, and clinical impor-
nce of the findings must also be weighed. The writing
mmittee believes that an enhanced system for selecting
tential performance measures that provides quantitative
mmaries of the impact on outcomes from adherence to the
easure is needed.
Translation of clinical evidence into quantitative summa-
es for use in the development of performance measurement
challenging but feasible (see Online Appendix C). In
rticular, explicit assessments of the clinical importance of
observed finding, such as whether: 1) the outcome was
portant and 2) whether the range of possible “true”
fferences between the treatment groups represents a clini-
lly important difference in outcomes (see example E in
gure 1 of Online Appendix C) will enhance the understand-
g of the benefit. The writing committee believes that no
rd and fast rules of minimal clinically important differences
n be created outside the context of a particular intervention
d outcome. But converting both survival and health status
.g., being asymptomatic, having a clinically important
provement in function or health-related quality of life)
nefits of treatment into meaningful summary metrics, such
number needed to treat with corresponding measures of
certainty, could help writing committees establish a stan-
rd for their use in creating a performance measurement set.
eporting quantitative measures of comparative evidence,
ch as Bayes factors, will also help writing committees in
eir decision-making. Regardless of the approach used,
riting committees should be explicit as to which outcomes
d benefits were considered clinically important in recom-
ending that an intervention be developed into a perfor-
ance measure. This process would be much more straight-
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Performance Measurement Methodology: New Insights November 16, 2010:1767–82rward if clinical trialists, when designing their studies,
plicitly stated what defined a clinically important difference
outcomes for each of the end points assessed in the trial.
ch routine reporting would markedly simplify the incorpo-
tion of study results into guidelines and performance
easures.
The Task Force on Performance Measures recommends
amining the evidence and range of clinically important
nefits to provide quantitative evidence with which to assess
e potential benefit of a proposed performance measure. A
rticular advantage to this approach is its formal specifica-
n of clinical benefit and the ability to systematically
corporate the range of available clinical evidence into a
ansparent analysis demonstrating the confidence with which
benefit of a certain magnitude might be gained from
idespread adoption of the clinical practice. An explicit
lineation of the clinical logic used to create a performance
easure should be disclosed, and a formal process for
aluating existing evidence should be developed with the
al of different performance measures writing committees
ely selecting similar processes of care from which to create
rformance measures. Such a process would have the added
vantage of minimizing potential conflicts of interest among
embers of a performance measures writing committee. The
ask Force on Performance Measures recognizes that for-
ally integrating available evidence into a framework to
fine the clinical significance of a benefit is labor-intensive.
eally, this would be done by guidelines writing committees,
t this is not always the case (9). Although it is not to be
plied that it is the role of performance measures writing
mmittees to conduct such analyses, it is important that
plicit articulation of the clinically meaningful benefit of
troducing a performance measure be demonstrated and
ferenced before the measure is created and selected. The
CCF/AHA Task Force on Practice Guidelines is examining
ternative approaches to grading clinical evidence. On com-
etion of this process, a more standardized approach can be
veloped.
.3. Costs and Performance Measures
he creation of a performance measure implies that all
igible patients (see Section 3.1) for that measure should
ceive, or at least be considered for, the therapy. The writing
mmittee believes that it is important to consider both the
st-effectiveness and total cost burden of potential perfor-
ance measures before selection. Although these may change
er time, explicitly quantifying the cost-effectiveness of
eatments at the time that performance measures are created
aligned with the Institute of Medicine (IOM) goal for a
ore efficient healthcare system and will minimize the
elihood that unintended economic consequences for soci-
y and hospitals emerge from adopting a measure (7). It is
t necessarily the role of performance measure writing
mmittees to conduct formal cost-effectiveness analyses, but
e writing committee believes that it is important to consider
ch analyses during selection of performance measures so
at the societal outcomes, including financial outcomes, of
plementing performance measures can be transparent.ost-effectiveness analysis should occur before or be concur- font with performance measure recommendations, should be
nducted by parties free of conflicts of interest, and should
eferentially use the societal perspective in defining cost-
fectiveness (10). In some situations, therapies are both more
fective and less costly than the standard of care (i.e.,
minant treatments). When this occurs, there is strong
stification to promote the intervention to a performance
easure because it is likely to both improve care and lower
sts. Although other issues may preclude the selection of a
minant treatment as a performance measure (e.g., feasibil-
of implementation), such treatments represent an ideal
portunity for creating performance measures. In most
rcumstances, however, effective therapies are also associ-
ed with increased costs. This creates a need to balance costs
ainst benefits attained, especially because there are com-
ting demands for the limited resources available to govern-
ents and societies for improving the health of populations.
There is no consensus on how cost considerations should
integrated into decisions about performance measures.
raditionally, value has been defined as the absolute effec-
eness of a given therapy compared with an alternative,
nditional on the cost of that therapy (i.e., the incremental
st-effectiveness ratio [ICER]) (11). Unfortunately, although
ost cost-effectiveness studies have been conducted from a
cietal (i.e., population-wide) perspective, significant het-
ogeneity remains in study designs (e.g., in-trial analyses
rsus Markov models), costing methods (e.g., microcosting
rsus macrocosting), measures of effectiveness, assump-
ns, and time horizons (e.g., 3 years versus lifelong), and
ere is no consensus as to what ICER threshold (if one
ould even be put forth) would be considered cost-effective
0,12). Because of these considerations, there are significant
itations in comparing ICERs across studies. For example,
e ICER for implantable cardioverter-defibrillator therapy
r primary prevention varies from $34,000 to $235,000 per
ality-adjusted life-year across different cost-effectiveness
udies, depending on which patient subpopulations are con-
dered (13–15). Moreover, a cost-effectiveness analysis is
t sufficient to fully appreciate issues of cost because it does
t provide a transparent reporting of the total cost burden of
e intervention to society, which is determined by the cost of
e therapy and the prevalence of the condition for which the
erapy is indicated. As such, 2 therapies could have identical
ER estimates but vastly different impacts on a healthcare
dget with competing demands.
There are other cost considerations for performance mea-
res. In some cases a therapy may be more effective and less
stly from a societal perspective, but its implementation may
ancially penalize clinicians or hospitals (e.g., if the therapy
events hospital readmissions or is poorly reimbursed by
yers, such as higher nurse–patient ratios). In these circum-
ances, when a patient’s benefit is expected to increase and
e total costs to society should decrease, realignment of
sfunctional economic reimbursements is needed to better
ign the financial paradigm so that the performance measures
n be implemented without disadvantage to a particular
mponent of the healthcare system.
Finally, providing incentives through pay for performance
r physician compliance with performance measures may
al
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November 16, 2010:1767–82 Performance Measurement Methodology: New Insightsso have unintended consequences on cost-effectiveness.
ch incentives may lead to physicians “gaming” the system.
y using strategies such as aggressive screening and overdi-
nosis, clinicians can appear to achieve better performance
ith some performance measures (e.g., achieving higher rates
hemoglobin A1C [HbA1C] of 7.0 for patients with
abetes mellitus and blood pressure control for patients with
pertension) because their sicker patient population is “di-
ted” with patients having an early stage or milder forms of
condition (16). Such efforts only lead to increased popula-
n costs for treatment, decreased average net effectiveness
treatment, and, consequently, decreased cost-effectiveness
.e., higher ICERs). Moreover, the use of artificial thresholds
warrant payments may present a problem by rewarding a
actice that achieves that threshold (e.g., lowering HbA1C
om 7.1 to 6.9) rather than making a more substantive
provement in patient management (e.g., lowering HbA1C
om 12.0 to 7.5).
Recognizing both the responsibilities of advancing a more
ficient healthcare system and the existing limitations and
ck of standardized methods in assessing costs and cost-
fectiveness, the Task Force on Performance Measures
lieves that a working committee should be created to
velop recommendations and standards for applying consid-
ations of cost and cost-effectiveness to the creation of
rformance measures, including any potential medicolegal
nsequences of explicitly considering cost considerations in
rformance measures. Because all performance measures
riting groups will confront the challenge of having to
tegrate costs into their selection process, an overarching
rategy needs to be developed and implemented.
. New Insights Into the Construction
f Performance Measures
.1. Use of Exceptions in
erformance Measures
ne area of performance measure creation that has garnered
gnificant attention in the past few years is the subject of
clusions. As noted in the initial methodology report (1),
ccasionally the denominator will exclude subsets of pa-
nts within the target population and the dimension of care
r the performance measure” (p 1153). These exclusions
ight more accurately be termed exceptions because the data
om these patients should still be captured for purposes of
ternal quality improvement analyses, even though the data
ay not be included in performance measurement reports.
his also implies that the performance measure was at least
nsidered for each potentially eligible patient, a primary
al of performance measures and the quality improvement
at they are intended to facilitate. Provisions for exceptions
ould be made in most process and outcome measures that
e used for accountability, including both provider compen-
tion (pay for performance) and public reporting purposes. It
less critical to provide for exceptions when measures are
ed solely for internal quality improvement, although col-
ction and use of these measures could still be useful to
ysicians in analyzing practice patterns. A detailed discus- ofon of the logic for this perspective is provided in Online
ppendix D.
According to a useful construct developed by the American
edical Association–Physician Consortium for Performance
provement (PCPI), exceptions to the use of process-based
rformance measures can be documented on the basis of
edical, patient, or system reasons (17). These major cate-
ries are further delineated into subcategories:
edical Reasons
Contraindicated (patient history of allergy, potential ad-
verse drug reaction, other)
Not indicated (already received/performed, not likely to
benefit, other)
Intolerant (therapy tried and patient could not tolerate it)
Other medical reason(s)
atient Reasons
Patient preference
Social reason(s)
Religious reason(s)
Economic reason(s)*
Other patient reason(s)
stem Reasons
Resources to perform services not available
Insurance coverage/payer-related limitations
Service/treatment to be provided by another physician
Other reasons attributable to healthcare delivery system
The principal advantage of such a categorization is the
creased burden of data collection. Rather than listing and
llecting data on each potential contraindication—and given
e virtually infinite number of unique situations that likely
ist to justify when a performance measure should be
sponsibly withheld from a potentially eligible patient—it is
w possible to merely select the category for which the
rformance measure is not appropriate. The writing com-
ittee continues to support this framing, given its advantages
improving the feasibility of performance measurement, but
cognizes that there are potential problems with both the
producibility of assigning a specific contraindication into
e correct category and the possibility of “gaming” the
rformance assessment efforts by incorrectly excluding po-
ntially eligible patients. To correct misclassification, either
ditional staff training or more accurate coding of electronic
edical records (EMRs) is likely to be needed. Professional
hics and a structured audit system are the 2 most effective
eans of minimizing intentional manipulation of patient data
achieve artificially better performance reports. Selective
diting of practices with a large proportion of potentially
igible patients with exclusions might be one way of ensur-
lthough the PCPI has placed economic reasons under System Reasons for
clusion because insurers can greatly influence both the tier and level of copay-
ents that patients are required to pay, the writing committee thought that the
oice to buy a medication is ultimately one made by the patient, and if the patient
ose not to buy an expensive medication, it was appropriate to include this
clusion within the Patient Reasons category. Because the exclusion of a patient
m the denominator of a performance measure is not influenced by the category
the exclusion, this should not alter current estimates of performance.
in
th
ex
be
m
ex
tie
R
ac
tio
en
m
or
“p
cu
ac
ex
pr
(e
pa
su
fr
do
co
pr
an
ou
su
3
O
O
th
an
re
da
fa
In
ad
co
th
m
pl
br
si
pe
im
ta
in
to
in
ad
an
fo
ne
us
th
pr
be
ac
un
ad
ad
de
ad
w
m
im
fo
ch
ta
as
m
m
tio
cl
w
ar
he
ad
st
th
at
(2
in
m
1.
2.
3.
4.
5.
6.
7.
st
pe
ex
to
ri
vi
ha
re
w
ou
1772 Spertus et al. JACC Vol. 56, No. 21, 2010
Performance Measurement Methodology: New Insights November 16, 2010:1767–82g more accurate categorization of exclusions. Importantly,
e writing committee believes that if a patient has a potential
clusion but receives the treatment, then that patient should
included in both the numerator and denominator of the
easure. Finally, it is recognized that the use of patient-level
clusions has the potential to sustain or exacerbate dispari-
s in care. In its report, “Unequal Treatment: Confronting
acial and Ethnic Disparities in Health Care,” the IOM
knowledges that poor (or culturally insensitive) presenta-
ns of treatment recommendations may potentially influ-
ce patient decisions (18). To the extent that the quality of
edical explanations presented to different racial, ethnic, sex,
age groups varies, then patients may refuse treatment—a
atient-centered” exclusion—even though a better or more
lturally sensitive explanation might have led the patient to
cept the therapy and receive it. This underscores the need to
amine not only actual performance rates, but also the
oportion of providers’ populations excluded so that outliers
.g., those with large proportions of potentially eligible
tients excluded) can be identified for further investigation.
In summary, the Task Force on Performance Measures
pports the application of exclusions by removal of patients
om the denominator. If a patient with a potential exclusion
es in fact receive treatment, then the patient should be
unted in both the numerator and denominator. This ap-
oach recognizes that some contraindications are relative,
d if a clinician believes that the benefits of a treatment
tweigh its risks, then the clinician should receive credit for
ccessfully fulfilling the performance measure.
.2. Considerations in the Use of
utcomes Measures
utcomes measures are emerging as a critical component of
e measurement portfolio. In 2007, the Centers for Medicare
d Medicaid Services (CMS) began to publicly report the
sults of its National Quality Forum (NQF)–approved 30-
y mortality measures for patients admitted with heart
ilure and acute myocardial infarction (AMI), respectively.
2008, a 30-day mortality measure for pneumonia was
ded, and in 2009, 30-day readmission data for these
nditions were added (19). Additional organizations, such as
e Society for Thoracic Surgeons, have NQF-approved
ortality measures. These measures are understood as com-
ementing the process measures because they provide a
oader perspective on the quality of care provided (20).
The Task Force on Performance Measures recognizes
gnificant strengths and limitations in the use of outcomes as
rformance measures. First, there is no debate as to the
portance of clinically meaningful outcomes, such as mor-
lity and health status (21). It therefore follows that the most
terpretable and potentially important performance measures
patients are outcomes measures. Potential limitations
clude the fact that some patients are more likely to have
verse outcomes regardless of the quality of care received,
d that the system should encourage, not discourage, care
r such high-risk patients. One method for preventing
gative consequences from treating the sickest patients is the
e of risk adjustment to “level the playing field.” But even
e best risk-adjustment models can explain only a modest booportion of the observed variation in outcomes. This may
a limitation if other unmeasured patient characteristics
count for differences in outcomes or a strength if the
measured variance is due to differences in quality. In
dition, for many outcomes, no well-validated risk-
justment models exist.
The Task Force on Performance Measures recognizes that
bate continues regarding the inclusion of specific risk-
justment factors. A particularly controversial issue is
hether race and socioeconomic status should be included in
odels. Some experts argue that these variables can carry
portant prognostic information that can improve the per-
rmance of the models and perhaps serve as surrogates for
ronic diseases or poorly managed conditions before hospi-
l admission. Others argue that these characteristics may be
sociated with the quality of care and that their inclusion
ay “adjust away” quality differences among providers,
aking it possible that those caring for vulnerable popula-
ns who perform poorly will not be identified. Finally, the
inical interpretation of models that adjust for race or sex
ould suggest that different outcomes for blacks or women
e acceptable and could undermine the goal of equity in US
alth care (7). Consequently, the CMS measures do not
just for race because of the concern of creating different
andards of care by the use of these variables.
In 2006, the AHA published a consensus statement with
e endorsement of the ACCF that articulated the key
tributes of outcomes measures suitable for public reporting
2). In developing the statement, the writing group, which
cluded clinicians, quality experts, a statistician, and policy-
akers, identified the following 7 preferred attributes:
clear and explicit definition of an appropriate patient
sample
clinical coherence of model variables
sufficiently high-quality and timely data
designation of an appropriate reference time before which
covariates are derived and after which outcomes are
measured
use of an appropriate outcome and a standardized period
of outcome assessment
application of an analytic approach that takes into account
the multilevel organization of data
disclosure of the methods used to compare outcomes,
including disclosure of performance of risk-adjustment
methodology in derivation and validation samples
The Task Force on Performance Measures supports these
andards in developing valid and useful outcomes-based
rformance measures, although several clear challenges
ist in their application.
An example of such a challenge is in the use of outcomes
evaluate the quality of coronary revascularization. Current
sk-adjustment methods are useful for comparing one pro-
der’s performance against all other studied providers who
ve performed that procedure. But these same risk-adjusted
sults may not be appropriate for comparing one hospital
ith another, leading to errors in interpretation. Current
tcomes-based mortality performance measures exist for
th bypass surgery and percutaneous coronary intervention
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ssible that 2 institutions with identical patient populations
d performances may look very different. Online Appendix
outlines such a potential scenario for both periprocedural
ortality outcomes and efficiency when bypass surgery and
I are examined independently or together. To facilitate
ese comparisons between hospitals, it would be more
propriate to redefine the population of analyzed patients as
ose with significant obstructive coronary artery disease
ther than create one stratum for those undergoing PCI and
other for those being treated with bypass surgery. Conse-
ently, the writing committee favors, wherever possible,
ing a clinical condition and state rather than a procedure as
e basis for applying an outcomes-based performance mea-
re. Nevertheless, all of the domains articulated by this
port are similarly complex, and transparency by writing
mmittees is needed to support and promulgate outcomes-
sed performance measures, a clear priority for performance
easurement development.
Another outcome measure relates to patient health status.
veral performance measurement sets include the assess-
ent of patients’ symptoms and function—a process—as
easures of healthcare quality meeting the dimension of care
sociated with serial monitoring of patients (23,24). The
sults of these assessments, although not currently reported,
ould be a clinically important outcome measure and could
ovide quantitative information on the variability in symp-
m control and quality of life of outpatients with coronary
sease or heart failure. A recent national study of primary
re clinics in Australia examined the proportion of each
inic’s patients with coronary disease who had weekly or
ore frequent episodes of angina. The results showed that
though 14% of clinics had no patients with weekly angina,
18% of clinics, more than half of patients had weekly
gina (weekly episodes of angina across the 207 clinics
nged from 0% to 100%) (25). However, until robust
sk-adjustment models are developed, these outcomes are
ely better used as tools for quality improvement than
countability.
The use of outcomes measures as indicators of quality are
rrently best understood as tools to assist hospitals and
althcare professionals to understand their performance.
ecause not all adverse events represent a failure of quality,
ven that some events cannot be averted even with the
ghest-quality care, the goal of outcomes-based assessments
to show relative differences in performance across delivery
stems so that those with the worst performance may reflect
ways to improve care or to learn from those with the best
rformance.
.3. Numbers of Measures
he proliferation of agencies and entities developing perfor-
ance measures, often with different methodological rigor,
als, and perspectives, is creating an unmanageable burden
r providers that threatens to undermine the stated goal of
rformance measurement: to improve the quality of health
re. Not only do professional organizations, such as the
CCF, the AHA, and the PCPI, create performance measures
ithin a given disease, but payers (e.g., CMS, United Health- wre, Blue Cross/Blue Shield) and other accrediting bodies
.g., the National Committee for Quality Assurance
CQA]) also create unique measures for the same condi-
n(s). Consequently, even when the same process of care is
ing evaluated, subtle differences in measure specifications
n lead to a marked administrative burden in properly
oviding the requisite data, as well as differences in results.
is therefore possible that different assessors examining the
me patients may reach different conclusions about a pro-
der’s performance. Because these differences can be attrib-
able to the method of assessment rather than the quality of
re provided, they have the potential to undermine trust and
nfidence in the system and can impair the capability of
rformance measurements to be used to improve care. The
ask Force on Performance Measures strongly supports the
ed to attain national consensus on a limited number of
easures that are universally accepted by all who are inter-
ted in performance assessment. Toward that end, the task
rce has been actively engaged with other professional
ganizations (e.g., the PCPI) and payers (e.g., the Joint
ommission, CMS, NCQA) to achieve consensus on defini-
ns of these measures. Yet the different perspectives of these
fferent bodies sometimes make reconciliation difficult.
hese differences are being negotiated to achieve balance
tween the available clinical evidence, the need to have
inical rather than administrative data, and feasibility. By
ing the same measures with the same definitions and a
asonable number of requisite data elements, consistent
llection and benchmarking is likely to be far more feasible.
The Task Force on Performance Measures recommends 2
ditional strategies to limit the number of measures. First,
e NQF has emerged as a national clearinghouse for vetting
d approving measures. On the one hand, this provides a
luable validation of the methodology used to create mea-
res and should theoretically elevate the quality of a perfor-
ance measurement set. On the other hand, it also accepts
easures from multiple different entities and has the potential
include measures that are built from data systems (e.g.,
ministrative data, proprietary date ranges surrounding a
minal event) that are opaque to clinicians, create adminis-
ative costs to understand and contest, and are not sufficiently
tionable so that they cannot be used for quality improve-
ent, the ultimate purpose of any quality-assessment pro-
am. Over time, a vetting process such as that provided by
e NQF should limit the number of measures to only those
at have the greatest potential to achieve the goal of
proving healthcare quality. Currently, CMS is reporting
ly measures that have been endorsed by the NQF.
The other promising approach is the creation of measure
ts for a given disease and rotation of selected measures over
e. By selecting a subset of measures to be used, a much
ore practical data collection effort that can be more easily
complished by a larger number of practices and institutions
n be undertaken and linked to meaningful quality improve-
ent. The national Door-to-Balloon (D2B) Alliance, which
duced delays in performance of primary PCI, is a notable
ample of this approach (26,27). What is needed is a
tional consensus on which measures should be used over
hat period of time. Ideally, such a decision-making body
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ams), regulators (for accreditation and public reporting),
ethodologists, and clinician representatives of those who
re for patients with the disease under assessment. Over
e, some measures would be retired and others introduced.
eally, when the subset of measures to be selected is defined,
easures from all of the multiple dimensions of care would
chosen so that a more comprehensive assessment of
ality health care could be attained. Those measures that are
t actively being used to quantify performance, either
cause there is inadequate variability in care, difficulties in
llection, or insufficient data to support their elevation as
rformance measures could still be used as quality metrics.
recent statement by the ACCF and AHA delineates the
fferences between these 2 types of measures (28).
.4. Modification and Retirement
f Measures
o date there has been a strong push to expand the number
d diversity of the performance measures portfolio to
ovide a more complete assessment of quality. However,
ere is also a need to periodically reconsider whether
eviously established performance measures should be mod-
ed or retired. This can occur for several reasons. First, new
ientific evidence may come to light that changes the
evious consensus views regarding a measure. An example
such a change is the use of early beta-blocker therapy for
tients with AMI (25). This performance measure was
iginally based on older trials that found that acute beta-
ocker therapy reduced postinfarction angina, arrhythmias,
d reinfarction risks. More contemporary trials, however,
at found acute beta-blocker therapy had no net impact on
ortality. Although such therapy reduced deaths from ar-
ythmias, it also increased risks for cardiogenic shock in
rtain subpopulations (29). On the basis of changes in
ideline recommendations, the ST-Elevation and Non–ST-
levation Myocardial Infarction Performance Measures Writ-
g Committee determined that early beta-blocker therapy
ould be dropped from the measure set, citing the complex-
required to distinguish patients who benefit from this
erapy from those who may be harmed (25). Similarly,
cause cigarette smoking is known to have a detrimental
pact on cardiovascular health and there is evidence that
gh-intensity behavioral and pharmacological therapies can
lp patients quit (30), smoking cessation counseling was
veloped as a performance measure for several conditions
4,25). But recent studies found a striking discordance
tween hospital performance on this measure and the rates at
hich patients actually quit smoking after myocardial infarc-
n (MI) (31,32). These data suggest the need for reevalua-
n of the smoking cessation measure.
A second reason for modifying or dropping a performance
easure is that collection of the data necessary to calculate
e measure is prohibitively complex or expensive. In some
ses these issues can be corrected with clearer instructions,
ore training, or minor changes in the numerator or denom-
ator of the measure.
A third reason for considering revision or retirement of a
easure is if its use has unintended adverse consequences. thn example of this was recently raised regarding a perfor-
ance measure to give intravenous antibiotics for
mmunity-acquired pneumonia within 4 hours of diagnosis.
lthough rapid administration of antibiotics is beneficial for
tients with pneumonia, the metric has been criticized
cause it may pressure clinicians to administer antibiotics
spite diagnostic uncertainty and may lead to overtreatment
3). Similar concerns have been raised that the current
CCF/AHA performance measure for D2B within 90 min-
es may lead to an increase in false-positive activation of
rdiac catheterization for patients with suspected ST-
evation MI (34). Although, in this case, the net benefits of
e D2B measure likely outweigh the risks, such examples
ghlight the need to carefully study the real-world impact of
rformance measures on provider care and patient outcomes
minimize unintended consequences (35).
A final reason for retiring a measure is when there is
ited to no room for further improvement in performance
d clinical practice reaches near-perfection. Currently, sev-
al MI performance measures are achieving asymptotic
eilings” of performance, including aspirin at arrival and
scharge, as well as beta-blocker use at discharge for patients
ith AMI (36). This achievement of near-perfection in
rformance should be seen as a celebration for the field and
mark of success of the performance measure and quality-
provement cycle. Yet, ever conscious of the burden of data
llection on the provider, some have argued for consider-
ion of retiring these metrics (37). Retirement of a perfor-
ance measure because of its success, however, should also
carefully monitored, because there is a risk that ending
tive measurement may lead to provider complacency and
timately a regression in performance. As noted in Section
3, recycling measures after a period of dormancy can both
sess the sustainability of the original performance assess-
ent effort and reinforce the need for this process of care.
. New Insights Into the Implementation
f Performance Measures
lthough the initial publication addressing the methodology
r measures creation and selection (1) explicitly called for
asibility testing before endorsement of performance mea-
res, this has rarely been done. The writing committee
anted to emphasize the importance of preliminary testing of
oposed measures in local, regional, or national projects
fore application for purposes of accountability. Congruent
ith this perspective, the NQF has begun issuing only
e-limited endorsements of proposed measures pending
monstration of their feasibility (38). A number of potential
rriers exist that could render an otherwise valuable poten-
l performance measure impractical to collect in clinical
actice.
The burden of data collection has emerged as a primary
allenge to implementation of performance measures. Not
ly do multiple performance measures often exist for a
rticular condition, but patients also have multiple diseases,
that it is not practical or possible to collect all measures for
l patients. This situation is compounded, in particular, by
e superiority of clinical data over administrative data one
en
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November 16, 2010:1767–82 Performance Measurement Methodology: New Insightscounters when seeking to quantify the quality of health care
9). The concepts described in this report, including elevat-
g the evidentiary threshold for endorsing a performance
easure, simplifying the inclusion/exclusion criteria, limiting
e number of measures, and retiring measures, may all lead
a more parsimonious, feasible measurement set for quality
provement and accountability.
A second critical aspect of collecting performance data is the
tegration of data collection through the process of providing
re. To the extent that extra work is needed to provide the data
quired for performance assessment, the more unsustainable
ch a program will become. An important responsibility of
rformance measures writing committees is to consider how
ta elements can be acquired throughout the transactions of a
inical encounter without requiring the collection and recording
additional data at a clinical visit. The challenge for the Task
rce on Performance Measures is to consider how multiple
easurement sets for different conditions, the similarity of
easure construction across diseases, and the totality of ACCF/
HA-approved measures might affect a clinical practice or
stitution.
Although EMRs would seem to offer a potential solution,
is is not currently the case. Many systems are unable to
port the collected data to other entities for performance
sessment and improvement, have data definitions that are
t congruent with those used by the developers of perfor-
ance measures (e.g., the ACCF/AHA data standards (40))
d may require “pop-ups” and other prompts that are
creasingly ignored by practitioners frustrated by the per-
ption that these aids are interfering with efficient patient
re. It is important that the effort to create exporting
nctions from EMR systems in standard formats be acceler-
ed so that those who use EMRs can more efficiently
rticipate in quality assessment and improvement efforts.
lthough alternatives, such as the patient flow sheets pro-
sed by the PCPI and prior ACCF/AHA performance
easures writing committees, still have some potential to
lp in performance measurement, a range of strategies for
ta collection needs to be considered by writing committees.
addition, it would be valuable for experts in medical
formatics to participate in such writing groups, given the
ique perspective and knowledge required to convert clini-
l logic into code.
Beyond the challenges of data collection, other insights
ve emerged over the past several years, including the need
develop “windows” around timeframes for performance.
r example, although it is reasonable to state that cholesterol
vels should be assessed every year in a patient with chronic
able coronary artery disease (23), a patient assessed in the
st week of December one year and the first week of January
the following year, 12½ months later, would not meet the
easure. Even more challenging is the current requirement
r a patient with atrial fibrillation to have an international
rmalized ratio (INR) measurement every month (41). Even
a patient had 10 to 12 INR assessments per year, which
ould generally be considered high-quality anticoagulation
anagement, many of these assessments might be within the
me month, whereas in other months there might be none.
he increasing use of home INR monitoring (42) further shmpounds the problem. Although there may be no solution
handling the example of serial cholesterol screening that
lls just outside a reporting window, the case of atrial
rillation might be better handled with a range of possible
sessments over the entire reporting window (e.g., 10
sessments within the reporting year) to minimize the
allenges in accurately representing the quality of care being
ovided.
A final lesson learned from early experiences in perfor-
ance measurement is the limited reproducibility of some
easures. For example, measures that encourage counseling
present an important dimension of care, but the quality of
livering counseling is difficult to quantify and yet may have
ofound influence on the ability of the activity to achieve its
sired outcomes. Also, as noted above, smoking cessation
unseling at the time of an MI has long been endorsed as a
rformance measure (43), yet recent data suggest that there
no overall association between smoking cessation counsel-
g and quit rates among smokers (32). In these studies,
wever, there was an association between the presence of an
patient smoking cessation program with patients stopping
oking after discharge (31). Although not definitive, these
dings suggest that the quality of counseling achieved may
fluence behavior and that failure to quantify or specify the
ality of counseling efforts may lead to a measure that is not
sociated with a clinically meaningful outcome. From this
perience, future performance measurement writing groups
ed to be confident that proposed performance measures can
adequately quantified so that the expected benefits from
herence to the measure can deliver the expected benefits in
tcome.
. New Insights Into the Analysis and
terpretation of Performance Measures
.1. Composite Measures
ombining measures or indicators of performance is a rela-
ely new consideration for assessing the quality of medical
re (44–46). The proliferation of efforts to measure, publicly
port, or reward healthcare providers has focused attention
the need to ensure that performance measures comprehen-
vely represent the quality of care, including sampling from
ong the multiple dimensions of care identified in the
iginal methods report (1). Composite quality of care mea-
res are increasingly being developed and deployed. A
mposite measure is a single measure of a construct that is
fined in terms of 2 individual measures. Although com-
site measures have many advantages, their construction,
velopment, and validation require more attention than that
eded for individual performance measures for a number of
asons (47–50).
Several lessons have been learned with the construction of
mposite quality measures. First, standard psychometric
operties of composites, such as reliability, accuracy, and
edictive validity, may be difficult to demonstrate. In partic-
ar, there may be no universal standard for some composite
easures. Consequently, other quality or health measures
ould be shown to be related to the composite. Individual
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ould contribute unique information to the underlying con-
ruct but at the same time should not differ from the other
mponents of the composite.
Second, the scoring methods used to create the composite
easure deserve serious consideration. A scoring method is
e rule used to combine the individual components of the
mposite. Common methods of combining individual com-
nents include all-or-none rules, where a success is declared
ly if all the individual components are met (conjunctive
oring); any rules, where a success is declared if any of the
ecified components are met (compensatory scoring); and
pirically weighted rules, where a number is produced using
e variability in the data to determine the weight of each
ecific component (factor analytically derived or item re-
onse theory derived). It is important to note, however, that
ese methods can lead to different conclusions.
Third, although missing data always pose a problem in any
alysis, the extent and impact of missing data can be hidden
pending on the scoring rule. Moreover, the scoring strategy
ay affect how missing data are handled. For all-or-none
les, if a single component of the composite is missing, then
e composite is missing; however, for any rules, as long as
e component is observed to have met success, the compos-
is observed. Strategies for handling missing data in the
oring rule must be transparent and valid.
Fourth, because some individual performance measures
ay be continuous (health status) and some may be binary
ithin-range blood pressure), statistically combining such
easures requires some thought. Most applied researchers
ill try to solve this problem by converting all individual
mponents into the same scale. Although this is an easy
lution, it is associated with a loss of information.
To address these challenges, the ACCF/AHA Task Force
Performance Measures has developed a position statement
composite measures (51). In addition, several professional
ganizations have developed recommendations for the de-
lopment of valid composite measures. The NQF has
eated a consensus report that has outlined a composite
aluation framework (52). Only those composite measure-
ents aligned with these recommendations will be consid-
ed as potential performance measures. The Task Force
Performance Measures recommends that composite per-
rmance measures follow the criteria described by the
CCF/AHA 2010 Position Statement on Composite Mea-
res for Healthcare Performance Assessment (51) as out-
ed in Table 2.
.2. Attribution
he majority of patients who have cardiovascular disease
ve multiple comorbidities and hence often have multiple
althcare providers within a single system of care or among
fferent systems of care. The complexity of measuring the
ality of coordinated cardiovascular care across multiple
althcare professionals and multiple settings is compounded
the difficulty in establishing the appropriate individual,
stitution, or healthcare system to which to assign attribution
accountability. Although some aspects of care and careordination are suitable for measurement at the level of the individual and appropriate accountability lies with the indi-
dual provider, others are more appropriate for measurement
the group, institutional, or system level.
The IOM has called for measurement approaches that
ster shared accountability (7). In such measures, all mem-
rs of the healthcare team(s) are held accountable for quality
d efficiency of care. The IOM has identified gaps in current
rformance measurement sets, including too few measures
patient-centered care, too few focusing on more than a
rrow time window, and too few with more than a narrow
cus of accountability beyond individual provider actions.
The NQF has endorsed measures for efficiency of episodes
care across the continuum of care (53) that focus on quality
d efficiency of care as perceived by the patient rather than
the healthcare provider or institution. In this construct the
amework for efficiency measurement addresses all levels of
e healthcare system, including individual providers, pro-
der organizations, and communities. From the patient’s
rspective, an episode of care is not a discrete encounter or
spitalization but a longitudinal experience that may last
onths to years or even an entire lifetime. For example, the
tient’s experience of an AMI does not begin and end with
e D2B time but encompasses the full spectrum from onset
chest discomfort through activation of an emergency
edical system, the hospital experience, discharge planning,
d return to long-term outpatient care and rehabilitation. In
me cases this experience also entails end-of-life planning
d palliative care. There are multiple real and potential gaps
care related to the many transitions in this definition of an
isode of care. For a hospital discharge, this would include,
ong others, medication reconciliation, transmission of the
scharge record, timeliness of postdischarge tests and ser-
ces, and patient understanding of the discharge plan and
re needed. New longitudinal measures need to be devel-
ed to fill gaps in the episode-of-care framework related to
ansitions from inpatient to outpatient settings (and vice
rsa), transitions among health systems, changes in the plan
care, and transitions and hand-offs among multiple provid-
s. Care coordination is essential because these transitions
n be disconnected, uncoordinated, and unsafe. Assigning
tribution in this framework is difficult and can only be
complished by assuming that there is shared accountability
r the quality of care provided across all providers, institu-
ns, and systems involved in the episode of care.
The concept of an accountable care organization, based on
e local delivery system (e.g., a multispecialty group practice
hospital and extended professional staff) from which
tients receive the majority of their care, rather than the
dividual practitioner, has been proposed as a first step in
eating the sense of shared accountability (54–56). The
tient-centered medical home also promotes shared account-
ility, because members of the team are equally responsible
r satisfactory delivery of the care plan (57). When patients
ansition among different delivery systems, however, mea-
res also need to aggregate care and care coordination across
tes and over time to operationalize the concept of shared
countability.
Thus, the concept of shared accountability may be effective
well-organized systems of care that exist for some patients,
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ould be associated with pitfalls and unintended conse-
ences if applied at the provider or institutional level for the
ajority of patients who transition over time among provid-
s and care sites. For example, length of stay will be
olonged if an institution transfers patients only to preferred
rsing homes (and a bed is not available at that facility), and
ble 2. Choosing Performance Measures
Choosing Perfo
lection Factors
nfidence that adherence to a
tential performance measure
uld result in meaningful
provements in clinically
portant outcomes
The methodology and logic by which a p
on meaningful clinical outcomes, should
sts of measure Explicit demonstration that application of
An estimate of the societal burden of mo
tcomes measures The outcomes to be considered must be
(symptoms, function, and quality of life),
Previously published recommendations fo
Risk adjustment, with carefully selected
be available to render observations interp
Where possible the population should rep
population.
easure Characteristics
e of exceptions Exclusions of patients from the denomina
● medical
● patient
● system-based reasons for why the pat
. of measures To minimize the number of measures, ef
be used for a specified period of time fo
developed.
Although performance measure writing c
should select only a subset of these for
The subset should include measures from
Measures should be retired when new e
outcomes or performance is so high that
Retired measures should be considered
asibility of data collection Data collection should occur prospectivel
data is not sustainable.
EMR companies need to create and supp
providers can participate in national qual
Measures need to be developed in a wa
for capturing performance that are pract
mposite measures The psychometric properties of these me
demonstrated.
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stitutions, and this may be beyond the ability of the medical
ofession to control. Finally, there would also be unique
ethodological issues in implementing a system of shared
tribution related to feasibility and determination of sample
zes needed for measurement. The Task Force on Perfor-
ance Measures recommends that the concept of shared
countability undergo appropriate field testing before there
further consideration of implementation. However, it
ould be prudent for hospitals to examine and reengineer
eir processes of discharge planning, patient education/self-
anagement, and communication with community physi-
ans and nurses if they wish to improve hand-offs and
crease 30-day mortality and readmission rates. This could
an important first step toward shared accountability.
. Conclusion
his update to the methodology of performance measure
lection and creation seeks to clarify key challenges and
portunities to elevate the science of quality assessment and
provement. Experience since the publication of the initial
ethodology report has identified critical opportunities to
prove the selection, construction, implementation, and
terpretation of performance measures (Table 2). With
spect to the selection of potential measures, there is a
essing need to elevate the transparency and rigor by which
e evidence supporting a performance measure is synthe-
zed, including a focus on clinically meaningful outcomes,
d the need to express the costs, both incremental cost-
fectiveness and overall societal costs, associated with a
tential performance measure. With respect to the construc-
n of performance measures, refinement of patient eligibil-
, considerations in the use of outcomes, and the number of
easures and their retirement have all emerged as important
portunities to improve the process of performance measure
eation. With respect to implementation of performance
easures, challenges have emerged that require ever-greater Nrutiny of the importance of potential performance measures
quality improvement and the need to create measures that
n be feasibly collected. Finally, with respect to the analysis
d interpretation of performance measures, careful attention
and testing of composite measures and the attribution of
rformance measures to appropriately accountable units
ed to be tested before implementation. Although these
commendations substantially increase the complexity and
ork involved in creating performance measures, the Task
rce on Performance Measures believes that following these
ocesses will elevate the consistency and quality of new
easures and improve the processes of quality improvement
that patients and society may benefit from higher-quality
rdiovascular care.
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